Evaluation of the safety and efficacy of intracameral triamcinolone acetonide in combined phacoemulsification and trabeculectomy

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002313

Enrollment

Unknown

Registered

2012-06-29

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

Triamcinolone acetonide group:Intracameral triamcinolone acetonide in combined phacoemulsification and trabeculectomy

Control group:Subconjunctival injection of dexamethasone after combined phacoemulsification and trabeculectomy

Eligibility

Sex/Gender

All

Age

40 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. Over 40 years of age; 2. Patients with visually significant cataract with the best corrected visual acuity less than 0.5; 3. Patients with primary glaucoma with an intraocular pressure of greater than or equal to 22 mmHg despite medical therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with other ocular pathologies such as cornea opacities, uveities, diabetes retinopathy, central retinal vein occlusion, et al.; 2. Secondary glaucoma because of trauma, uveities, neovascularization, et al.; 3. Past medical history of intraocular surgery; 4. Patients taking systemic immunosuppressants or adrenal corticosteroid.

Design outcomes

Primary

Measure	Time frame
Visual Acuity;Intraocular Pressure;Anterior Chamber Inflammation by cells and flar;	—

Countries

China

Contacts

Public ContactWang Bingsong

wangbingsong@gmail.com+86 15810023101

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026